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cell reconstitution and induces tolerance to bone marrow
grafts even in the absence of conditioning providing a new
tool for clinical translation especially in childrenwith SCID or
hemoglobinopathies.LATE EFFECTS/QUALITY OF LIFE
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Background: Hematopoietic cell transplantation (HCT) is a
resource-intensive therapy. The economic costs to the
medical system have been well-described; however,
few studies have prospectively assessed the ﬁnancial
consequences of HCT for patients and their families.
Methods: We report preliminary data from a prospective
study of ﬁnancial hardship related to HCT. We mailed a
41-item questionnaire to adult patients approximately six
months post-allogeneic or autologous HCT at three sites
(Dana-Farber Cancer Institute [DFCI], Roswell Park Cancer
Institute, and Mayo Clinic Arizona). The questionnaire was
developed with input from a focus group of HCT nurses and
social workers, and underwent formal cognitive debrieﬁng
with HCT patients. HCT-related clinical outcomes associated
with hardship will be assessed at one year. We present the
ﬁnancial experience of the ﬁrst cohort of DFCI patients.
Results: As of October 1, 2014, of 174 surveys mailed, 124 had
been received (71%). Patients were a median of 174 days
post-HCT. The mean age was 57.6 years, 49% had had an
allogeneic transplant, 95% were white, 75% were married,
24% had at least one child at home, 52% were currently
working at least part-time or taking a leave of absence, and
46% had at least a bachelor’s degree. Patients came from 10
states; the top three were MA (45%), ME (14%) and NY (13%).
Compared to before transplant, 48% reported a decline in
monthly household income. Nearly half (48%) were also only
somewhat, slightly or not at all satisﬁed with their present
ﬁnancial situation, and 41% reported somewhat, moderate or
extreme difﬁculty in making bill payments. About one out of
ﬁve (21%) reported substantial hardship, deﬁned as not
having enough money at the end of the month, and 52.4%
(95% CI [43.5, 61.3]) reported either unsatisfactory income,
difﬁculty making payments, or substantial hardship.
Transplant type, gender, age, race, employment and college
degree were not signiﬁcantly associated with substantial
hardship; however, being unmarried (p< .03) and lower
income level (p<.02) were. Patients reported several
ﬁnancial coping strategies post-HCT (see table), which




Percent of all respondents 47% 43%
Odds ratio for substantial
hardship vs. other [95% CI]
6.4 [ 2.2, 18.7] 3.5 [ 1.4, 8.9]Conclusions: The majority of HCT patients face ﬁnancial
difﬁculties, particularly those who are not married or have
more limited income. Coping strategies vary, although
spending on prescription medicines is largely preserved.
Several strategies are much more prevalent among those
with substantial hardship. The ultimate effects of ﬁnancial
burden on HCT outcomes remain to be demonstrated.59
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Background: Approximately 10% of older (65y) individuals
in the general population demonstrate frailty (Collard RM et
al. J Am Geriatr Soc. 2012;60:1487-92). HCT recipients are at
risk for accelerated aging, given the high-intensity
therapeutic exposures and excessive burden of morbidity
after HCT. We examined the prevalence and predictors of
frailty in elderly (65y) HCT survivors.
Methods: Participants included 276 older HCT survivors
(median age at study participation: 70 y (65-84), who had
undergone HCT (allogeneic: n¼83, autologous: n¼196)
between 1985-2010. Median time from HCT was 8.9y
(3.7-29.1). Following well established survey-based screening
tools for frailty (Pialoux T et al. Geriatr Gerontol Int.
2012;12:189-97), all participants completed a self-report
survey that included questions pertaining to: low leanmuscle
mass, self-reported exhaustion, low energy expenditure, slow
walking speed, and muscle weakness. Prefrailty included 2,
while frailty included 3 conditions.
Results: The prevalence of prefrailty and frailty was 28% and
13%, respectively.Predictors of pre-frailty and/or frailty
After adjusting for age at enrollment, sex, race, education
and employment status, survivors with low income (annual
household income <$50,000/annual personal income
<$20,000) were 3.2 times more likely to report pre-frailty
and/or frailty (OR¼3.2, 1.5-6.9, p¼0.003); furthermore,
allogeneic HCT survivors with a history of cGvHD were 2.7
times more likely to report pre-frailty and/or frailty (OR¼2.7,




Cut back on prescribed
medicine
24% 59% 5%
7.9 [ 3.0, 20.7] 7.2 [2.0, 25.6] 8.4 [1.4, 48.6]
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Allogeneic HCT survivors with cGvHD were signiﬁcantly
more likely to report frailty than autologous HCT survivors
(29% vs. 10%, p¼0.004), but the prevalence rate for frailty
among allogeneic HCT survivors without cGvHD was
comparable to autologous HCT survivors (14% vs. 10%, p¼0.4).
Multivariable logistic regression revealed that allogeneic
HCT survivors with cGvHDwere 4.6 foldmore likely to report
frailty than autologous HCT survivors (OR¼4.6, 1.6-13.2,
p¼0.004). Of note, age at HCT, age at study participation,
race/ethnicity, year of HCT, and diagnosis were not associated
with frailty.
Conclusions: Our study demonstrates that the prevalence of
frailty among older survivors of allogeneic HCTwith a history
of cGvHD is about three times that seen among older
individuals in the general population, as well as that seen
among autologous HCT recipients. On the other hand, the
prevalence of frailty among older survivors of autologous
HCT as well as allogeneic HCT recipients without cGvHD is
comparable to that in the general population. Lower income,
possibly reﬂecting compromise in nutrition, or access to
medical care, is associated with increased prefrailty and
frailty. The study identiﬁes vulnerable populations among
older HCT survivors needing close monitoring to prevent and
manage morbidity.60
Cardiac CT Imaging Is a Feasible Screening Strategy for
Coronary Artery Disease (CAD) in Long Term Allogeneic
Stem Cell Transplant (Allo-SCT) Survivors
Natasha A. Jain 1, Marcus Y. Chen 2, Sujata Shanbhag 2,
Prathima Anandi 1, Kit Lu 1, Priyanka A. Pophali 1, Neil Dunavin 1
, Sawa Ito 1, Eleftheria Koklanaris 1, Christopher S. Hourigan 1,
A. John Barrett 1, Minoo Battiwalla 1. 1 Hematology Branch,
National Heart, Lung, and Blood Institute, NIH, Bethesda, MD;
2 Cardiology Branch, National Heart, Lung, and Blood Institute,
NIH, Bethesda, MD
Introduction: Signiﬁcant increases in CAD risk and
cardiovascular events have been described in long-term
allo-SCT survivors compared to age and gender-matched
population controls. Since pharmacologic interventions,
such as statins, positively inﬂuence the evolution of CAD and
subsequent cardiovascular events, an effective screening
strategy is essential. Screening for CAD has hitherto relied
upon clinical assessments such as the Framingham cardio-
vascular risk score but the optimum screening strategy in
this unique population is undeﬁned.
Method: We conducted a prospective non-randomized
study using cardiac CT to evaluate Agatston coronary calcium
scoring by CT with concomitant coronary CT angiography
for screening asymptomatic allo-SCT survivors. 55 subjects
(32 males; 23 females) with a median age of 41 years (range
17 - 69) at transplant and a median follow up interval of 10
years (range: 4-21) were studied. Angiography was excluded
in 5 subjects with renal dysfunction. CAD was deﬁned as
presence of lesions on CT angio and/or calcium score > 0 (for
subjects without angiography). 10-year Framingham scores
were also calculated: 3 were classiﬁed as high risk, 5 were
intermediate and 47 were low risk.
Results: CAD was detected in 24 of 55 (44%) subjects.
Characteristics of coronary plaques were: 21.5% calciﬁed, 55%
mixed calciﬁed/non-calciﬁed, and 23.5% non-calciﬁed. Cor-
onary lesions were mostly non-obstructive (86%), but
obstructive lesions were seen in 14%. Lesion distributions by
arterial territory were: left main 12.8%, left anterior
descending 30.8%, left circumﬂex 23.1% and right coronaryartery 33.3%. Additionally, 16 (67%) patients with CAD had
either aortic root or mitral valvular calciﬁcation.
Radiation exposure during the procedure was negligible,
at a median of 0.72 mSv for the coronary calcium score and
1.12 mSv for the coronary CT angiogram. There were no
adverse events.
Coronary calcium scoring had a sensitivity of 73% (95% C.I.
55% to 85%) and a speciﬁcity of 100% (95% C.I. 86% to 100%)
compared to CT angiography. In addition, calcium score was
able to detect CAD in 2 of 5 subjects who could not have
angiograms because of renal dysfunction. Current (2010
AHA/ACC) guidelines suggest a role for coronary calcium
scoring for screening asymptomatic non-transplant in-
dividuals with intermediate Framingham risk. However,
cardiac CT detected CAD in 18 of 47 (38.3%) low Framingham
risk survivors. Coronary calcium scoring alone may be
adequate for screening and avoids the use of IV contrast.
Conclusion: Accelerated CAD was detected in 44% of our
alloSCT survivors by cardiac CT screening. Coronary calcium
score with or without CT angiogram is a safe, feasible and
sensitive screening technique for CAD. It is informative even
in asymptomatic, low-risk survivors and is far more sensitive
than the Framingham risk score.61
Long-Term Follow-up after Hematopoietic Stem Cell
Transplantation for Patients with Fanconi Anemia: A
Single Center Experience on 157 Patients Surviving 2 or
More Years after Transplant
Carmem Bonﬁm 1, Lisandro Ribeiro 1, Samantha Nichele 2,
Marco Bitencourt 3, Mary Eapen 4, Mary E.D. Flowers 5,
Gisele Loth 1, Cilmara Kuwahara 6, Ana Luiza Melo Rodrigues 3,
Vaneuza Araujo Moreira Funke 7, Ricardo Pasquini 8. 1 Bone
Marrow Transplantation Unit, Federal University of Paraná,
Curitiba, Brazil; 2 Bone Marrow Transplantation Service,
Federal University of Parana, Curitiba, Brazil; 3 Federal
University of Parana, Curitiba, Brazil; 4 CIBMTR, CIBMTR/
Medical College of Wisconsin, Milwaukee, WI; 5 Clinical
Research Division, Fred Hutchinson Cancer Research Center,
Seattle, WA; 6 Bone Marrow Transplantation Unit, Hospital
Infantil Pequeno Príncipe, Curitiba, Brazil; 7Hematology,
Federal University of Parana, Curitiba, Brazil; 8 Internal
Medicine, Federal University of Parana, Curitiba, Brazil
Allogeneic transplantation is the only curative treatment
for the hematological complications of Fanconi anemia.
Survival after transplantation has improved dramatically
over the past decade, however, only limited data are avail-
able regarding late complications after transplantation.
Therefore, we studied late complications in 157 patients who
survived for at least 2 years after their ﬁrst transplantation,
between 1988 and 2011. The median follow up of this cohort
is 9 years (range 2e25). Marrow failure was the most com-
mon indication for transplantation (80%) and most (71%)
grafts were from a related donor. Bone marrow was the
predominant graft (89%). Chimerism studies were available
for 147 of 157 (94%) patients; at last follow up, 110 of 147
(76%) patients reported donor chimerism >95%, 27 (18%),
between 90-95%, 8 (5%), <90% and the remaining 2 patients
(1%), <30%. The 2-year cumulative incidence of chronic
GVHD at 2 years was 35%. At study entry 32 of 55 patients
with chronic GVHD were receiving immunosuppressive
treatment. The probabilities of overall survival for patients
who survived at least 2 years was 95%, 90% and 79%, 5, 10 and
15 years after transplantation. Late mortality was associated
with transplant period (prior to 2003), history of chronic
GVHD and, occurrence of squamous cell carcinoma (SCC).
